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Fxperimental allergic encephalitis (EAE) ~ is a  disease produced in animals by the 
injection, in  complete Freund's adjuvant  (CFA), of  encephalitogenic protein  (EP) 
derived from brain. The evidence is strong that the disease results from an immune 
response to the injected antigen and, until recently, it was believed that delayed sensi- 
tivity to  the  EP was directly related to  the production of disease. It is possible to 
chemically  modify  the  EP  by  treating  it  with  2-hydroxy-5-nitro-benzyl bromide 
(HNB) which blocks the single tryptophan residue and renders the molecule inactive 
in producing disease (1).  The HNB-treated molecule is therefore termed  nonenceph- 
alitogenic protein (NEP). 
The entire amino acid sequence of the EP derived from brain has recently been re- 
ported  (2),  and  the major encephalitogenic determinant has been characterized and 
synthesized (3). It is a nonapeptide having the amino acid sequence Phe-Ser-Trp-Ala- 
Glu-Gly-Gln-Lys.  Additional studies showed that three amino acids were essential for 
the cncephalitogenic property of the peptides: Trp,  Gin, and Lys, although the Lys 
could be replaced by another amino acid, Arg. The other amino acids in the sequence 
could be altered without destroying the encephalitogenic activity of the peptide (4). 
We  have  used  these  well-characterized  antigens  to  further  study  cellular 
imnlunity in relationship to EAE. The present communication reports the re- 
sults  of  experiments  to  determine  cellular immune  response  to  the  EP,  the 
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NEP,  and  the synthetic peptides in animals which have been immunized with 
the various encephalitogenic and nonencephalitogenic peptides,  in animals im- 
munized with the EP  and the NEP,  and in animals protected from disease by 
immunization with the NEP.  The results suggest a  dissociation between cellu- 
lar immunity  to the EP  and the production  of EAE. 
Materials and Methods 
Encephalitogenic Basic Protein (EP). -This was purified from bovine spinal cord myelin as 
described  (5). The preparation included lipid and acid extractions,  precipitation of contami- 
nants at pH 7, dialysis in acetylated tubing, diethylaminoethyl (DEAE)-cellulose chromatog- 
raphy and, finally,  gel filtration. The homogeneity of the preparation was demonstrated  by 
polyacrylamide gel electrophoresis, immunoelectrophoresis, and immuno-double diffusion. 
Nonencephalitogenic Modified Protein (NEP).--This was prepared by treating the EP with 
2-hydroxy-5-nitro-benzyl bromide (HNB)  (6) as described (1). Briefly,  the EP was dissolved 
TABLE I 
Amino Acid Sequence of Peptides Used in These Experiments 
Peptide  Encephalito-  Amino acid sequence*  genie 
Tryptophan 
1 
2 
3 
4 
5 
6 
Yes  Phe-Ser- Trp-  Gly-Ala-Glu-Gly-Gln-Lys 
Yes  Ser-Arg-Phe-ALA-Trp- Gly-Ala-Glu-Gly-Gln-Lys 
No  Ser-Arg-Phe-Ser- Trp-  Gly-Ala-Glu-Gly-Gln 
Yes  Ser-Arg-Phe-Ser- Trp-  Gly-Ala-ILU-Gly-Gln-Lys 
Yes  Ser-Arg-Phe-Ser- Trp-  Gly-Ala-Glu-Gly-Gln-ARG 
No  Ser-Arg-Phe-Ser- VAL- Gly-Ala-Glu-Gly-Gln-Lys 
No  Ser-Arg-Phe-Ser- PI-IE-Gly-Ala-Glu-Gly-Gln-Lys 
* The amino acids which differ from  those of the encephalitogenic determinant  of  the 
encephalitogenic protein are indicated by bold-face type. 
in 8 ~t urea,  treated with dry acetone containing HNB, and purified  on a  Sephadex G-25 
column (Pharmacia Fine Chemicals Inc., Piscataway, N.J.). 
Encephalitogenic and Nonencephalitogenic Peptides.--The peptides were synthesized accord- 
ing to the solid-phase procedure described by Merrifield (7)  and purified by Sephadex gel 
titration.  (Some of the peptides were synthesized by Dr. Fred Westall of Salk Institute, San 
Diego, Calif.) The amino acid sequence of the peptides utilized in these studies is shown in 
Table I, and the amino acid content, as determined by the Beckman 121 Automatic Amino 
Acid Analyzer (Beckman Instruments Inc., FuUerton, Calif.) is shown in Table II. This analy- 
sis shows a close correlation between the expected and observed amino acid content. 
Immunization  and Testing.--Random-bred  guinea pigs each weighing approximately 500- 
600 g were utilized. They were immunized and tested according to the following schedules.  The 
skin tests and the in vitro studies were performed on different groups of animals to avoid any 
possible effect of the injection of the skin test antigen on the response in vitro. Immunized 
animals which had been used for skin testing were kept alive and observed for signs of disease. 
Immunization  with Encephalitogenic and Nonencephalitogenic Peptides.--44  guinea pigs were 
immunized with 20 #g of the various synthetic peptides in saline emulsified  with an equal 
volume of  CFA  (H37Ra,  Difco Laboratories,  Detroit, Mich.).  Injection schedule for each 
animal was 0.1  ml administered intradermally into each foot pad and 0.2  ml given subcuta- 158  EAE  WITHOUT  CELLULAR  IMMUNITY 
neously. Skin  tests were performed  on day  10 after  immunization since previous study had 
shown that the intensity of the reaction diminished from days 13-17 as the disease progressed 
(5).  Macrophage migration and lymphocyte stimulation studies were  also performed on the 
10th day after immunization. The number of skin tests and in vitro  studies which could be 
done using the peptides as the test antigens was necessarily limited by the high dose of peptide 
required for these studies (200/~g per test or 1200 #g for complete testing of each animal) and 
the necessity that the peptides be synthesized. Four additional guinea pigs (two for skin testing 
and  two for  in  vitro  studies)  in  each subgroup were immunized with  100 #g of each of the 
peptides to determine whether a larger dose of the immunizing antigen might produce different 
results. 
Immunization with EP.--To test the response to the peptides in guinea pigs immunized with 
the whole protein, guinea pigs were inoculated with 250 #g of the EP in saline emulsified with 
CFA in a  manner similar to that described for immunization with the peptides. Skin tests and 
studies in vitro were performed 10 days after immunization. 
TABLE  II 
A mino A cld Composition of Synlhelic Peptides* 
Molar ratio:~ 
Peptide 
Lys  Arg  Ser§  Glu  Gly  Ala  Val  Ilu  Phe 
Tryptophan  1.19  --  0.86  1.86  1.78  0.86  --  --  1.44 
1  1.17  0.98  .63  2.32  2.07  1.89  --  --  0.93 
2  --  1.17  1.74  2.27  2.23  0.84  --  --  0.77 
3  1.22  1.00  1.00  1.1l  2.43  1.15  --  1.01  0.96 
4  Not tested 
5  1.00  1.01  1.17  2.25  2.40  1.16  1.08  --  0.91 
6  1.18  1.05  0.99  2.08  2.39  1.27  .04  --  1.98 
* Tryptophan was destroyed during acid hydrolysis. 
Number of residues in  each peptide  was  based  on number of cycles performed  in  the 
synthesis. 
§ The molar ratio  of serine is minimal because no correction has been made for possible 
losses during acid hydrolysis. 
Immunization with NEP.--To test the immunologic responses of the guinea pigs immunized 
with NEP, which does not produce disease, guinea pigs were inoculated with 250 t~g of NEP in 
saline enmlsified with CFA.  Skin tests and studies in vitro were performed  10 days after im- 
nmnization. 
]~rotectionfrom  Disease wilh NEP.--Guinea pigs were injected with 1 mg of NEP emulsified 
in CFA.  1 and 2 wk later they were again injected with 1 mg of NEP in Freund's incomplete 
adjuvant. This procedure has been shown to protect the animals from EAE after subsequent 
challenge with EP  (8). Skin tests, lymphocyte stimulation studies, and macrophage migration 
tests were performed 1 month after the last injection. A second group of guinea pigs was simi- 
larly injected with a protective dose of NEP,  and was challenged with the injection of 250 ~*g 
of EP in CFA  1 month after  the last injection of NEP.  Skin tests and in vitro studies were 
performed 10 days after challenge. 
Controls.--These animals were immunized and tested exactly as described for the peptides, 
except that the immunizing antigen was 250  ~g of bovine gamma globulin (BGG)  or keyhole 
limpet hemocyanin (KLH). 
Skin Tests.--Skin tests were performed on a shaved area of the flank by intradermal injec- 
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skin test were EP, 50 ug; NEP, 50 #g; purified protein derivation of tubercule bacillus (PPD), 
10 #g; BGG, 10/zg; peptides, 200 ptg. The diameter of the erythema and the induration was 
carefully observed and recorded at the end of 1, 2, 3, 5, and 6 hr (immediate reactions) and at 
the end of 24 and 48 hr (delayed reactions). Reactions were considered positive if they consisted 
of erythema and clear-cut induration of 5 mm or greater. 
Lymphocyte Response.--Lymph node lymphocytes were cultured according to our modifica- 
tions of the method of Duttou and Eady (9) : 107 cells were cultured in 4 ml of Eagle's minimal 
essential medium  for suspended  cultures  (Spinner's medium,  Grand Island Biological  Co., 
Grand Island, N. Y.)  containing 100 units of penicillin and 100 #g of streptomycin/ml, 1% 
L-glutamine, and 5% calf serum. All cultures were prepared in triplicate. The following doses of 
antigen in 0.1 ml of saline were added to each 4 ml of culture: EP, 50/zg; peptides, 200 #g; 
PPD  (Merck  Sharp  &  Dohme,  West Point,  Pa.),  10/zg;  and phytohemagglutinin  (PHA) 
(Difco Laboratories). The antigens were added at the beginning of the cultures, and the mix- 
ture was incubated at 37°C in an atmosphere of 5% CO2 and 95% air for 2 days, at the end of 
which period thymidine-2-14C (specific activity, 59.2 mCi/mole) (New England Nuclear Corp., 
Boston, Mass.) was introduced into each culture tube. The cells were harvested in the cold 24 
hr later by serially suspending them once in saline, twice in 5% trichloroacetic acid, and once in 
methanol. The precipitate was dissolved by incubation in 1 ml of Hyamine at 56°C  for 1 hr, 
transferred to counting vials, and prepared for scintillation counting by adding 12 ml of Omni- 
fluor (New England Nuclear Corp.) in toluene. The radioactivity was measured on a Packard 
liquid scintillation counter  (Packard Instrument Co., Downers Grove, Ill.). In a few experi- 
ments, cell death was evidenced by uniformly low radioactivity (20-40 cpm) in all tubes and 
by lack of any stimulation by PHA; these results were eliminated from our calculations and the 
experiments were repeated. The cell death did not occur with cells from any particular group of 
animals. Results were analyzed by the Mann-Whitney U  test.  Statistical analysis indicated 
that for the EP, less than 5% of cultures from control animals would produce a ratio of  1.4 
or greater when tubes with EP were compared with tubes without EP. 
Macrophage Migration.--Macrophage  migration was performed as described by David et al. 
(10). Peritoneal exudates were induced by the intraperitoneal injection of 30 ml of light mineral 
oil (Marcol)  (Humble 0il  & Refining Co., Houston, Tex.)  into the guinea pigs 7 days after 
immunization. 3 days later the cells were harvested by washing the peritoneal cavity with 200 
ml of Hanks' solution. The packed cells were suspended in Spinner's medium, 7.5% by volume, 
and capillary tubes were filled with the cell suspension. The tubes were sealed and spun in the 
cold for 5 rain at 900 rpm. They were cut at the cell-fluid interface and placed in Mackaness- 
type culture chambers, two tubes per chamber. All chambers were prepared in duplicate. The 
chambers were filled  with Spinner's medium containing 100 units of penicillin and 100 #g of 
streptomycin/ml, 1% L-glutamine, 15% normal guinea pig serum, and 0.1 ml of saline contain- 
ing test antigens in the same concentrations as for lymphocyte culture, except that PHA was 
not used.  (The PPD utilized in the macrophage migration studies was kindly supplied by the 
Ministry of Agriculture, Fisheries, and Food, Weybridge, England.) The chambers were sealed 
and incubated for 24 hr at 37°C.  The cell image was projected and traced, and the area of 
migration measured using a  planimeter. The areas of migration in duplicate test chambers 
(four tubes) were averaged, and the results were expressed as percentage of migration of peri- 
toneal cells in experimental chambers with antigen compared with that in the control chambers 
containing no antigen. Results of the in vitro studies were analyzed by the Mann-Whitney U 
test.  Statistical analysis indicated that less than  5%  of  the cultures from control animals 
would result in migration below 71% for EP or 62% for NEP when migration in chambers 
with antigen was compared with migration in chambers without antigen. 
RESULTS 
The results of the study of cellular immunity in guinea pigs immunized with 
the tryptophan peptide, which is encephalitogenic and has the same amino acid 160  EAE  WITHOUT CELLULAR IMMUNITY 
sequence  as  that  appearing in  the EP,  are shown  in Table III. The  animals 
showed  both  immediate  and  delayed skin test  reactivity to the EP,  and  the 
migration of their peritoneal exudate cells was inhibited by the EP; however, 
there was  no  increase in DNA  synthesis of their lymph node lymphocytes in 
response to EP. Only one of six animals showed delayed skin reactivity to NEP, 
and  there was  no  significant lymphocyte stimulation  or inhibition of macro- 
phage migration by this antigen. As expected, the animals showed cellular im- 
TABLE III 
Results  of the  Stingy  of Celhdar  Immunity  in  Guinea  Pigs Immunized  with the  Tryptophan 
Peplide 
Test 
antigen 
No. of  Induration  Induration  positive 
EP 
NEP 
BCG 
KLH 
PPD 
PHA 
Skin test  I  In vitro 
Immediate  Delayed 
5.8  4-  1.2; 
3.2  -4-  1.4 
0.8  4- 0.8 
NT 
6.2  ±  1.2 
NT 
5  (6)§ 
2  (6) 
1  (6) 
NT 
5  (6) 
NT 
4.5  ±  0.7 
1.3  4-  0.8 
0.0  4- 0.0 
NT 
13.6  ±  0.6 
NT 
No. of  I 
positive 
5  (6) 
1  (6) 
1  (6) 
NT 
6  (6) 
NT 
Lymphocyte 
response 
Macrophage 
migration 
E/C*  r  % 
1.4  ±  0.2  57.7  4-  3.4ll 
(6)  (6) 
1.0  4-  0.1  90.3  ±  5.3 
(6)  (6) 
NT  100.8  4-  5.6 
j  (6) 
1.0  4- 0.0  NT 
(6) 
2.8  4-  0.5  56.7  4-  6.9 
(6)  (6) 
27.2  ±  6.8  NT 
(6) 
NT, not tested. 
* Counts per minute m  experimental tubes with antlgen/counts per minute in control 
tubes without antigen. 
All results reported as mean  4- S~M. 
§ Numbers in parentheses are numbers  of animals tested. 
I] Significantly different from controls (P <  0.05). 
munity  to  PPD,  since  they had  been  immunized  by  antigen  in  CFA,  which 
contains tubercle bacilli. The stimulation by PHA of the lymphocytes appeared 
less than that observed in the control animals, but the difference is not statisti- 
cally significant. 
The results of immunization with peptide 1  (Tables I  and II) are shown in 
Table IV  and  illustrated in  Fig.  1.  This peptide has  an  amino acid sequence 
different from that of the EP, but it produces disease since the three amino acids 
essential for this activity are present.  Four guinea pigs were immunized with 
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same in both groups and so have been pooled. Only one of six animals showed 
delayed skin reactivity to  the EP.  Lymphocytes derived from  these animals 
did not show increased DNA synthesis in response to this antigen, nor was there 
inhibition of the migration of their peritoneal exudate cells. The observation of 
80 %  migration with EP  or NEP  added to the chamber was the same as that 
which  occurred when  these antigens were added to cells from control animals 
immunized  with  BGG.  The  animals  did show  cellular immunity  to  the  im- 
TABLE IV 
Results of the Study  of Cellular Immunity in Guinea Pigs Immunized  with Peptide i 
Test 
antigen 
No. of 
Induration  positive 
EP 
NEP 
BGG 
PPD 
Peptide 1 
PHA 
Skin test  In vitro 
Immediate  Delayed 
No. of 
Induration  positive 
mm 
0.S  ±  0.8~  1  (6)§ 
4.2  4-  1.2  4  (6) 
0.7  4- 0.6  0  (6) 
5.7  ±  1.8  4  (6) 
6.0  2  (2) 
NT  NT 
~m 
0.8  ±  0.8 
1.5  4- 0,6 
0±0 
16.7  4-  2.0 
5.5 
NT 
1  (6) 
0  (6) 
0  (6) 
6  (6) 
2  (2) 
NT 
Lymphocyte  Macrophage 
response  migration 
E/C*  % 
1.2  ±0.1  81±4.5 
(6)  (6) 
1.1  4- 0.1  82  ±  3.1 
(6)  (6) 
1.0  ±0,1  80±2.7 
(5)  (5) 
1.8  ±  0.3  44  4-  6,9 
(6)  (6) 
3.3  68  4-  7.7 
(2)  (4) 
69  4-  22.0  NT 
(6) 
Tryptophan peptide,  Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys 
Peptide 1,  Set  -Arg-Phe-ALA-Trp-Gly-Ala-Glu-Gly-Gln-Lys 
NT, not tested. 
* Counts per minute in experimental tubes with antigen/counts per minute in control 
tubes without antigen. 
J~ All results reported as mean 4- SE~. 
§ Numbers in parentheses are numbers  of animals tested. 
munizing  antigen,  peptide  1,  by all three measures.  There  was  no reactivity 
with NEP,  and they did show immunity to PPD,  as expected. 
The  results  of  immunization  with  peptide  2  are  shown  in  Table  V.  This 
peptide has the same amino acid sequence as that in the EP, but does not pro- 
duce  disease because it lacks the terminal lysine. Five of six animals showed 
delayed skin reactivity to EP,  but cellular immunity to this antigen was not 
demonstrated by studies in vitro. Similarly, delayed skin reactivity to NEP was 
observed without demonstrable cellular immunity by the in vitro studies. The 
results  with  the  control  antigens,  BGG,  PPD,  and  PHA,  were  as  expected. 162  t~AE  WIT~IOUT  CELLULAR  IMMUNITY 
Cellular immunity to the immunizing antigen,  peptide 2,  could not be tested 
in  vivo or  in  vitro  as  this  antigen  produced  nonspecific reactions  in  control 
animals. 
The results of immunization with peptide 3 are shown in Tables VI and VII. 
This peptide is encephalitogenic but has an amino acid sequence different from 
that of EP. No cellular immunity to the EP could be demonstrated in animals 
which had been immunized with 20 #g of peptide 3,  even though  animals im- 
munized with this dose of antigen regularly develop EAE. Peptide 3 produced 
inhibition  of migration of peritoneal exudate cells derived from these animals, 
FIc.  1.  Results of macrophage migration studies in guinea pigs immunized with the  EP 
peptide 1, and BGG. 
but  did  not  cause increased DNA  synthesis  in  their  lymphocytes. When  the 
animals were immunized with a  larger dose (100/~g)  of peptide 3,  cellular im- 
munity  to EP  could be demonstrated by all  three  criteria.  (The lymphocyte 
response was borderline.) 
Guinea pigs which were injected with each of the encephalitogenic peptides, 
and  not  further  manipulated,  developed  clinical  EAE  and  died.  Detailed 
histologic evaluation of these animals will be reported elsewhere.  2 Some of the 
2  Hoffman, P., and L. E. Spitler. EAE: A comparison of histologic changes produced by 
immunization with the encephalitogenic peptides, encephalitogenic protein, and whole spinal 
cord. Manuscript in preparation. SPITLER~  VON  MULLER~ ~UDENBERG~ AND  EYLAR 
TABLE  V 
Results  of the Study of Cellular Immunity in Guinea Pigs Immunized with Peptide 2 
163 
Test 
antigen 
EP 
NEP 
PPD 
BGG 
PHA 
Skin test  In vitro 
Immediate 
Induration 
mm 
3.7  ±  1.6~ 
4.5  ±  1.4 
7.3  ±  1.6 
0 
NT 
Delayed 
qo. of  Induration  ositive 
mrrb 
(6)§  5.2  ±  0.4 
(6)  4.5  ±  1.0 
(6)  16.5  ±  0.9 
0  1.5  4-  0.5 
NT  NT 
No. of 
positive 
5  (6) 
4  (6) 
6  (6) 
0  (6) 
NT 
Lymphocyte 
response 
E/C* 
1.0  ±  0.1 
(4) 
1.0  ±  0.0 
(4) 
4±1.0 
(4) 
0.6  ~  0.1 
(4) 
124  =t=  30.5 
Macrophage 
migration 
% 
84  ±  4.2 
(6) 
86  -4-  4.8 
(6) 
61  :t:  6.4 
(6) 
91  -4-  7.0 
(6) 
NT 
Tryptophan peptide,  Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys 
Pepfide 2,  Ser-Arg-Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln 
NT, not tested. 
* Counts per minute in experimental tubes with antigen/counts per minute in control: 
tubes without antigen. 
All results reported as mean -4- SEM. 
§ Numbers in parentheses are numbers of animals tested. 
TABLE  V[ 
Results  of the Study of Cellular Immunity in Guinea  Pigs Immunized  with 20 Izg of Peptide 3 
Skin test  In vitro 
Immediate  Delayed  Test antigen 
No. of  Induration  No. of positive  Induration  positive 
Lymphocyte  Macrophag~ 
response  migration 
mm  mm  E/C*  % 
EP  0  0  (2)*  0  0  (2)  1.0  (2)  103  (2) 
NEP  0  0  (2)  0  0  (2)  0.8  (2)  96  (2) 
PPD  14.0  2  (2)  23.0  2  (2)  2.7  (2)  59  (2) 
BGG  0  0  (2)  0  0  (2)  0.8  (2)  94  (2) 
Peptlde 3  NT  NT  NT  NT  0.9  (2)  56  (2) 
PHA  NT  NT  NT  NT  55  NT 
Tryptophan peptide,  Phe-Ser-Trp  -Gly-Ala-Glu-Gly-Gln-Lys 
Peptide 3,  Ser-Arg-Phe-Ser-Trp-Gly-Ala-ILU-Gly-Gln-Lys 
NT, not tested. 
* Counts per minute in experimental tubes with antigen/counts per minute in control 
tubes without antigen. 
Numbers in parentheses are numbers of animals tested. 164  EAE  WITHOUT  CELLULAR  IMMUNITY 
TABLE  VII 
Results of the Study of Cellular  Immunity in Guinea Pigs immunized with 100 #g of Peptide 3 
Skin test  In vitro 
Test antigen  Immediate  Delayed 
Lymphocyte  Macrophage 
No. of  Induration  No. of  response  migration  Induration  positive  positive 
mm  mm  E/C*  % 
EP  5.5  2  (2):~  5.0  2  (2)  1.4  (2)  63  (2) 
NEP  5.5  2  (2)  4.5  1  (2)  1.4  (2)  65  (2) 
PPD  8.5  2  (2)  14.0  2  (2)  1.9  (2)  55  (2) 
BGG  1.0  0  (2)  0  0  (2)  0.8  (2)  89  (2) 
PHA  NT  NT  NT  NT  92  (2)  NT 
NT, not tested. 
* Counts  per minute in  experimental  tubes  with  antigen 'counts per minute  in  control 
tubes without antigen. 
Numbers in parentheses are numbers of animals tested. 
TABLE  VIII 
Results of the  St~uty  of Celhdar Immunity  in  Guinea Pigs Immunized  with Encephalitogenic 
Protein 
Test 
antigen 
Peptide 1 
Peptide 4 
EP 
NEP 
PPD 
BGG 
PHA 
Skln test  In vitro 
Immediate  Delayed 
Induration 
m~ 
1.1  4-  0.5 
0 
9.0  4-  1.0 
8.0  4-  0.7 
13.0  4-  1.3 
NT 
NT 
No.  o~  Induration  positive 
1.7  4.  0.6~  1  (8)§ 
1.5  4.  1.3  3  (4) 
4.0  4-  1.4  3  (6) 
3.6  4-  1.4  4  (8) 
7.5  4-  1.6  5  (6) 
o  0  (8) 
NT  NT 
No, of 
positive 
o  (s) 
0  (4) 
6  (6) 
7  (s) 
6  (6) 
o  (8) 
NT 
Lymphocyte 
2.7 
2.3 
2.8 
0.9 
162 
Macrophage 
response  migration 
E/C*  % 
NT  102  ±  12.1 
(6) 
NT  118  4-  19.3 
(3) 
4-  0.6[1  68  -t-  3.21] 
(6)  (10) 
4.  0.51]  73  4.  6.1 
(6)  (10) 
4-  O.6  47  -4-  3.9 
(6)  (10) 
±  0.1  93  4.  9.7 
(5)  (8) 
4.  38.2  NT 
(6) 
Try-ptophan peptide,  Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys 
Peptide 1,  Ser-Arg-Phe-ALA-Trp-Gly-Ala-Glu-Gly-Gln-Lys 
Peptide 4,  Ser-Arg-Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-ARG 
NT,  not tested. 
* Counts per minute  in  experimental  tubes  with  antigen/counts  per  minute 
tubes without antigen. 
J; All results reported as mean 4- sE~. 
§ Numbers in parentheses are numbers of animals tested. 
II Significantly different from controls (P  <  0.05). 
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guinea pigs immunized with encephalitogenic  peptides  and subsequently used 
for skin testing did not develop clinical disease. This could  be due to suppres- 
sion  of disease  by the  amount  of antigen  necessary for skin  testing;  alterna- 
tively,  the guinea pigs  could  have developed mild disease which  was  not  de- 
tected  clinically  and  they may have  subsequently  recovered. 
The results  of the studies  of cellular immunity in animals  immunized with 
EP are listed in Table VIII. It is evident that animals immunized with EP did 
not  show  cellular  immunity,  as  measured  by  skin  reactivity  or macrophage 
TABLE IX 
Results  of the Study  of Cellular  Immunity  in  Guinea  Pigs  Immunized  with  Noneneephalit- 
ogeniv Protein (NEP) 
Skin test  In vitro 
Immediate  Delayed  Test antigen 
No. of  Induration  No. of 
positive  positive 
Lymphocyte  Macrophage 
culture  migration 
mm  E/C*  % 
EP  5  (6)~  6,1  4- 0.7§  5  (6)  2.8  4-  o.811  60  4-  5.311 
(6)  (6) 
NEP  6  (6)  1.3  4-  0.4  6  (6)  8.4  4-  2.71I  35  4-  6.011 
(6)  (6) 
PPD  4  (6)  11.6  4-  1.3  6  (6)  1.4  4- 0.3  45  4-  6.0 
(6)  (6) 
BGG  0  (6)  0  0  (6)  0.9  4-  0.1  89  4-  2.8 
(6)  (6) 
KLH  NT  NT  NT  85.0  -4- 25.1 
(6) 
PHA  NT  NT  NT 
NT, not tested. 
* Counts  per minute  in experimental  tubes  with antigen/counts per minute  in control 
tubes without antigen. 
:~ Numbers in parentheses are numbers of animals tested. 
§ All results reported as mean 4- SE~. 
11 Significantly different from control (P <  0.05). 
migration,  to either of the two encephalitogenic peptides tested.  Peptides 2, 3, 
and 5 could not be utilized for test purposes because they  gave nonspecific re- 
actions in  animals  immunized  with  BGG.  Some guinea pigs immunized  with 
EP were tested with the peptides alone without simultaneous  testing with other 
antigens (EP or PPD) because of the possibility that testing with other antigens 
at the same time might diminish  the response to the peptide;  however,  these 
animals similarly did not show reactions to the test peptides.  As expected, the 
animals  immunized with EP  did  show delayed  sensitivity  to EP by all  three 
measures. 
The results of the study of cellular immunity in the guinea pigs immunized 
with NEP, which does not produce disease,  are shown in Table IX. Five of six 166  EAE  WITHOUT  CELLULAR  IMMUNITY 
animals showed delayed reactivity to EP. As expected, they also showed de- 
layed reactivity to the immunizing antigen, NEP; this was stronger than the 
reaction to the EP, suggesting that cellular reactivity to the HNB group is also 
involved in the reaction. Lymphocytes from the guinea pigs immunized with 
NEP responded to EP by increased incorporation of radioactive thymidine into 
DNA in vitro. They also responded to NEP and to PHA, but not to the control 
antigen, BGG. Migration of peritoneal exudate cells derived from these animals 
FIG.  2.  Effect of test antigens on migration of peritoneal exudate cells derived from guinea 
pigs immunized with NEP or with BGG. 
was inhibited by EP, NEP, and PPD, but not by BGG. These results are il- 
lustrated in Fig. 2. The animals inoculated with NEP and skin tested with EP 
were kept alive and observed for 2 months after immunization. None showed 
clinical signs of EAE. 
The results of the study of cellular immunity in the control guinea  pigs im- 
munized with BGG or KLH are shown in Table X. Some inhibition  of macro- 
phage migration was produced by the EP and NEP, and this was taken  into 
account in the statistical analysis of the data. 
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marized in Table XI. Guinea pigs which had received protective immunization 
with  the NEP  did not  show delayed skin reactivity to the EP,  but  they did 
show  both  immediate and  delayed skin reactivity to the  EP  after protective 
immunization with  the NEP  and  challenge with  the  EP  in  CFA.  All of  the 
guinea pigs showed  immediate and  delayed skin reactivity to  the NEP.  The 
results of the studies in vitro were similar in animals which had received pro- 
TABLE X 
Resets ~  Study ~  Cell~arlmmunityin  ControlGuinea  Pigslmmunized with BGGor KLH 
Skin  test  In vitro 
Test antigen  Immediate  Delayed 
EP 
NEP 
BGG 
KLH 
PPD 
PHA 
Peptide 1 
Peptide 4 
Induration 
mm 
0.4  +  0.3~ 
0.8  -¢- 0.5 
5.7  4-  1.5 
NT 
10  4-  1.2 
NT 
1.7  4-  1.0 
0 
!  Induration  e 
mm 
§  0.5  4-  0.3 
0.5 
12.4  4-  1.8 
NT 
18  -4-  1.7 
NT 
0.7  4- 0.6 
0 
No. o: 
positi~ 
0  (10 
o  (lo 
9  (10 
NT 
9  (10 
NT 
0  (6) 
0  (2) 
Lymphocyte 
response 
E/C* 
0.9  4-  0.04 
(6) 
0.9  4-  0.2 
(6) 
NT 
24.2  4-  4.8 
(6) 
0.9  4- 0.4 
(6) 
2O4  4- 56.3 
(6) 
1.0  4- 0.0 
(4) 
NT 
Macrophage 
migration 
% 
80  4-  5.1 
(11) 
71  4-  4.8 
(11) 
63  ±  8.4 
(11) 
NT 
78  4-9.9 
(10) 
NT 
83  4-0.9 
(4) 
NT 
NT, not tested. 
* Counts per minute in experimental tubes with antigen/counts per minute in control 
tubes without antigen. 
:~ All results reported as mean 4- sE•. 
§ Numbers in parentheses are numbers of animals tested. 
tective immunization with NEP  alone, or protective immunization followed by 
challenge with the EP in CFA. The EP and the NEP produced both inhibition 
of macrophage migration and lymphocyte stimulation of cells derived from the 
animals. None of these guinea pigs developed signs of EAE or died during an 
observation period of 2 months  after the last immunization. 
DISCUSSION 
The results reported here show that the cellular immune responses to the EP, 
the NEP,  and the synthetic peptides in general are those which would be ex- 168  lgAE  WITHOUT  CELLULAR  INIMUNITY 
pected according to the principles of cellular immunity, and are independent of 
whether  the  antigens  utilized  are  encephalitogenic  or nonencephalitogenie.  A 
complete dissociation between delayed sensitivity to the brain protein and the 
production of EAE has not before been reported; this is the first demonstration 
that it is possible to produce EAE in animals without cellular immunity to the 
brain protein and,  conversely, that it is possible to produce cellular immunity 
to the brain protein in animals which do not develop and, indeed, are protected 
from, the disease. 
As expected, guinea pigs immunized with the tryptophan peptide, which has 
the same amino acid sequence as that which  appears in the EP,  show cellular 
TABLE XI 
Results of Study of Cellular Immunity in Guinea Pigs Prolecled from EAE by Immunizalion 
with NEP 
Test 
antigen 
EP 
NEP 
PPD 
BGG 
PHA 
Protected with NEP not 
challenged with EP 
Skin test 
Immediate 
~¢  (2)§ 
2  (27 
0  (2) 
Protected  with NEP challenged with EP 
[  (  Skin test 
LyraphocytelMacrophage[  __  _  _ 
culture  migration  !  I 
Delayed  Immediate I Delayed 
0  (2)  4.0  (2)  46' (2)  2  (2)  2  (2) 
2  (2)  ! 2.7  (2)  i  30  (2)  2  (2)  2  (2) 
8.5  (2)  39  (2)  2  (2)  2  (2) 
0  (2)  2.0  (2)  I  88  (2)  0  (2)  0  (2) 
/6so  I 
Lymphocyte  Macrophage 
culture  migration 
E/C  % 
2.9  (1)  48  (1) 
8.2  (1)  58  (l) 
10.0  (1)  6l  (1) 
0.82  (1)  75  (1) 
184.0  (1) 
* Counts per minute in experimental tubes with antigen/counts  per minute in control 
tubes without antigen. 
~C Number of animals showing reactivity. 
§ Numbers in parentheses indicate number of animals tested. 
immunity to the EP as determined by skin testing and macrophage migration 
inhibition. By contrast, guinea pigs immunized with peptide 1 or with 20 ~g of 
peptide 3 do not show cellular immunity to the EP in vivo or in vitro, despite 
the fact that they do develop EAE. They do, however, show delayed sensitivity 
to the immunizing antigen. Both peptides 1 and 3 have amino acid sequences 
which are different from that in the EP. In view of the specificity of delayed 
sensitivity to the hapten and carrier (11-14), it is not too surprising that animals 
immunized with these peptides do not show delayed sensitivity to EP. Further, 
although guinea pigs immunized with peptide 2 do not develop EAE,  they do 
show delayed sensitivity to the EP; peptide 2 has an amino acid sequence which 
is the same as that which  appears in the native protein,  so this response also 
would  be anticipated  based  on  the  principle of the specificity of cellular im- 
mune responses. SPITLER,  VON  MULLER,  I~UDENBERG,  AND  EYLAR  169 
One could argue that we failed to demonstrate sensitivity to the EP in the 
animals immunized with peptides 1 and 3 because of the steric configuration of 
the EP when used as a test antigen in the in vivo and in vitro systems such that 
the encephalitogenic determinant might be hidden. That this is not the case is 
demonstrated by the fact that sensitivity to the EP can be demonstrated by 
in vivo and in vitro criteria in animals immunized with the tryptophan peptide. 
It is of interest that skin test reactivity and inhibition of macrophage migra- 
tion by the  EP  could be  demonstrated in  guinea pigs  immunized with the 
tryptophan peptide or with 100/~g of peptide 3, whereas the EP did not cause 
increased DNA synthesis in the lymph node lymphocytes derived from these 
animals. A  similar dissociation between skin test reactivity and macrophage 
migration on the one hand and lymphocyte stimulation on the other has now 
been reported in several different systems. We first reported this dissociation in 
guinea pigs immunized with the tobacco mosaic virus protein and tested with 
the antigenic peptides of this protein (15).  We noted a similar dissociation in 
patients  with  the  Wiskott-Aldrich  syndrome  after  treatment  with  transfer 
factor (16, 17). Using a tuberculin carbohydrate fraction as antigen, others have 
confirmed our findings (18). These observations led us to suggest that there may 
be two different kinds of thymus-derived lymphocytes or T  cells:  one which 
undergoes proliferation in response to antigen, and one which produces media- 
tors of cellular immunity, such as migration inhibitory factor (MIF). 
We believe  the  crucial  question is  the  mechanism by which  animals im- 
munized with the encephalitogenic peptides develop EAE,  although we were 
unable to demonstrate cellular immunity to the brain protein by the tests used. 
It is clear that sensitized cells, probably lymphocytes, are in some way involved 
in the pathogenesis of the disease, since EAE can be transferred by cells derived 
from animals immunized with brain protein (19-21)  but not by serum derived 
from these animals (22, 23)  even after direct intracerebral inoculation (24).  It 
is now recognized that the lymphocyte is a multipotent cell and that there are 
numerous biologic functions of lymphocytes and of the products of the inter- 
action of sensitized lymphocytes and antigen. These  cells  undergo increased 
RNA,  DNA,  and  protein  synthesis  and  produce  substances  with  activities 
including inhibition of macrophage migration (25,  26),  chemotaxis of mono- 
nuclear  cells  (27),  increased  DNA  synthesis  in  nonsensitized  lymphocytes 
(28-30),  "activation" of nonsensitized lymphocytes (31),  death of target cells 
(32),  and the production of skin reactions (33). Interferon (34)  and  immuno- 
globulins (35) are  also produced. It  is  now  recognized that  dissociation be- 
tween these various lymphocyte activities occurs.  Thus,  it would seem pos- 
sible that the sensitized lymphocytes in the animals immunized with the pep- 
tides might be reacting with the brain protein either directly or by producing 
a cell-free mediator, but that the reaction involved in producing disease is not 
one  of  the  reactions which we  have  measured in  this  study,  i.e.,  that  skin 
reactivity, production of MIF, and lymphocyte stimulation are not necessarily 
concomitants of this reaction. 170  EAE  WITHOUT CELLULAR  IMMUNITY 
The studies in the animals immunized with the EP confirm and extend pre- 
vious studies which have shown that animals immunized with brain  antigens 
show delayed sensitivity in vivo and in vitro to the brain antigens (36-38). The 
lack of response of these animals to the encephalitogenic peptides in vivo and in 
vitro is in accord with expected results based on the principles of cellular im- 
munity, since these peptides have amino acid sequences different from these in 
the immunizing protein. 
The demonstration that  animals  immunized with  NEP,  which  do not  de- 
velop disease,  show cellular immunity to EP has important  implications for 
investigators engaged in the study of cellular immunity. Inhibition of migration 
of macrophages,  or  of leukocytes, has  been  reported in  the  presence  of ap- 
propriate tissue antigens in diseases such as glomerulonephritis (39), Addison's 
disease  (40),  pernicious  anemia  (41),  ulcerative  colitis  and  Crohn's  disease 
(42), multiple sclerosis (43, 44), and the Guillain-Barr~ syndrome (44). Most of 
these investigators have at least suggested that cellular immunity can, there- 
fore, be considered to  contribute to the pathogenesis  of these diseases.  It  is 
probable that the cellular immunity that we have demonstrated in animals im- 
munized with NEP is directed toward a part of the EP other than the trypto- 
phan  peptide and  is,  therefore, unrelated  to the  disease-producing site.  It  is 
likely that  the same principle holds for human diseases in which  cellular im- 
munity to tissue antigens has been reported: cellular immunity may be directed 
towards parts  of the antigen unrelated  to production of the disease,  a  point 
which has not been clearly recognized by investigators involved in these studies. 
EAE is  the only "autoimmune" disease for which we have information re- 
garding the determinant necessary for the production of disease; there is no 
similar  information  concerning other  diseases.  In  the  human  diseases  men- 
tioned  earlier,  cellular immunity  to  tissue  antigens,  rather  than  causing  the 
disease, may well  result from the pathogenic process itself. A  parallel can be 
drawn to autoantibodies, initially thought to be pathogenic, that have now been 
found to accompany, but not cause, certain diseases. 
The animals protected from EAE by immunization with the NEP and sub- 
sequently challenged with  the EP show cellular immunity to the EP in vivo 
and in vitro, although they do not develop EAE. This study does not indicate 
the mechanism of the protection produced by immunization with NEP, but it 
does show that the mechanism is not the prevention of cellular immunity to the 
EP as has been postulated by others. It has been postulated that the induction 
of antibodies may be the mechanism of protection, and it has been shown that 
EAE can be prevented by the passive transfer of immune serum (23). However, 
if this is the case, the antibody does not prevent the cellular immune reaction 
from occurring in vivo, since the protected animals show skin reactivity to the 
injection of the EP. 
We have demonstrated a  dissociation between cellular immunity and EAE 
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macrophage migration, and lymphocyte stimulation. In the past it was thought 
that antibodies played a role in the pathogenesis of many autoimmune diseases, 
but subsequent study showed that in many of these diseases the antibody was 
secondary to the disease rather than being responsible for its production; there- 
fore, interest turned to delayed sensitivity in  these diseases,  because of the 
demonstrated cytopathic effects which can be produced in the cellular immune 
response. However, it is possible that cellular immunity, like antibody forma- 
tion, may be a  concomitant of the immunization process or a  result of tissue 
damage and, hence, unrelated to the pathogenesis of disease. 
The present study raises many questions about the mechanism of the pro- 
duction  of  EAE  in  animals  immunized with  encephalitogenic protein.  The 
pathogenesis of disease may not even be the same in animals immunized with 
EP as compared with animals immunized with the encephalitogenic peptides. 
The sensitized lymphocyte may react with antigenic determinants in the central 
nervous system to produce EAE but this reaction may not be mediated by the 
type of responses measured here. In this regard, it would be of interest to study 
the local production of the demyelinating antibody (45) utilizing a system such 
as ours. It may be also that an appropriate combination of cellular immunity 
and antibody production is necessary for the production of disease. 
The use of the well-characterized encephalitogenic and nonencephalitogenic 
peptides and highly purified preparations of brain protein and modified brain 
protein has made it possible to define some of the principles regarding the de- 
velopment of EAE. With the tools now available it should be possible to answer 
the questions raised in this paper regarding the pathogenesis of the disease. 
SUMMARY 
The encephalitogenic determinant of brain protein, a nonapeptide having the 
amino  acid  sequence  Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys, has  been  char- 
acterized and synthesized. In a previous study, analogues of this encephalito- 
genic peptide were synthesized and some were shown to be encephalitogenic while 
others were not. Guinea pigs were immunized with encephalitogenic peptides 
having amino acid sequences different from that in the native protein. These 
guinea pigs did not show cellular immunity in vivo (skin reactivity) or in vitro 
(lymphocyte  stimulation  or  macrophage  migration  inhibition)  to  the  en- 
cephalitogenic brain protein (EP) although they did show cellular immunity to 
the immunizing antigenic peptide. Guinea pigs immunized with an encephalito- 
genic peptide having the same amino acid sequence as the brain protein,  or 
with a  nonencephalitogenic peptide having the same amino acid sequence as 
the native protein but lacking the  terminal lysine, did develop cellular im- 
munity to the EP. Animals immunized with EP showed cellular immunity to 
this protein, but not to the encephalitogenic peptides. Animals immunized with 
nonencephalitogenic protein (NEP), prepared by altering the tryptophan resi- 
due of EP, did not develop disease but did show cellular immunity in vitro and 172  EAE  WITHOUT  CELLULAR  II~fMUNITY 
in vivo to the EP. Animals protected from disease by immunization with NEP 
similarly showed cellular immunity to EP. Thus, the results suggest a dissocia- 
tion  between  cellular  immunity  to  EP  and  the  production  of  experimental 
allergic  encephalitis  (EAE).  Animals  immunized  with  the  encephalitogenic 
peptides develop EAE, but do not show cellular immunity to EP, and animals 
immunized with NEP show cellular immunity to EP but do not develop EAE. 
A fresh approach to the examination of the pathogenesis of EAE is now possible 
through the use of these well-characterized antigens. 
We thank Dr. An-Chuan Wang for assistance in the amino acid analysis of the peptides. 
REFERENCES 
1.  Eylar, E. H., and G. A. Hashim. 1969. Allergic encephalomyelitis:  Cleavage of the 
C-tryptophyl bond in the encephalitogenic  basic protein from bovine myelin. 
Arch. Biochem.  Biophys. 131:215. 
2.  Eylar, E. H. 1970. Amino acid sequence  of the myelin basic protein. Proc. Natl. 
Acad. Sci.  U.S.A. 67:1425. 
3.  Eylar, E. H., J. Caccam, J. J. Jackson, F. C. Westall,  and A. B. Robinson.  1970. 
Experimental allergic encephalomyelitis:  synthesis of disease inducing site of the 
basic protein. Science (Wash. D.C.). 168:1220. 
4.  Westall,  F.  C., A. B. Robinson,  J. Caccam, J. Jackson, and  E.  H.  Eylar.  1971. 
Essential  chemical  requirements  for  induction  of  allergic  encephalomyelitis. 
Nature (Lond.). 229:22. 
5.  Eylar, E. H., J. Salk,  G. C. Beveridge,  and L. V. Brown.  1959. Experimental al- 
lergic encephalomyelitis,  an eneephaltogenic  basic protein from bovine myelin. 
Arch. Biochem.  Biophys. 132:34. 
6.  Barman, T. E., and D. E. Koshland, Jr.  1967. A colorimetric procedure for the 
quantitative determination of tryptophan residues  in proteins. J.  Biol.  Chem. 
242:5771. 
7.  Merrifield,  R. B. 1964. Solid-phase peptide synthesis.  III. An improved synthesis 
of bradykinin. Biochemistry.  3:1385. 
8.  Eylar, E. It. 1971. Basic A1 protein of myelin: relationship to experimental allergic 
encephalomyelitis.  In  Immunologic Disorders of the  Nervous System. L.  P. 
Rowland, editor. The Williams and Wilkins  Co., Baltimore, Md. 50. 
9.  Dutton,  R. W.,  and J. D.  Eady.  1964. An in vitro system for the study of the 
mechanism of antigenic  stimulation in  the  secondary response.  Im~nunology. 
7:40. 
10.  David, J. R., S. Al-Askari, H. S. Lawrence, and L. Thomas. 1964. Delayed hyper- 
sensitivity in vitro. I. The specificity of inhibition  of cell migration by antigens. 
J. Immunol. 93:264. 
11.  Benacerraf, B., and P. G. H. Gell. 1959. Studies  on hypersensitivity. 2. Delayed 
and  Arthus-type  skin  reactivity  to  protein  conjugates  in  guinea  pigs. 
Immunology. 2:53. 
12.  Benacerraf, B., and P. G. H. Gell. 1959. Studies on hypersensitivity. III. The re- 
lation between delayed reactivity to the picryl group of conjugates and contact 
sensitivity. Immunology. 2:219. SPITLER,  VON  MULLER,  ~UDENBERG,  AND  ILYLAR  173 
13.  Salvin, S. B., and R. F. Smith.  1960. The  specifidty of allergic reactions. I. De- 
layed versus Arthus hypersensitivity. J. Exp. Med. 111:465. 
14.  Gell, P. G. H., and B. Benacerraf. 1961. Studies on hypersensitivity. IV. The rela- 
tionship between contact and delayed sensitivity: a study on the specificity of 
cellular immune reactions. J. Exp. Med. 113:571. 
15.  Spitler, L. E., E. Benjamin, J. D. Young, H. Kaplan, and H. H. Fudenberg. 1970. 
Studies on the immune response to a characterized antigenic determinant of the 
tobacco mosaic virus protein. J. Exp. Med. 131:133. 
16.  Levin, A. S., L. E.  Spitler,  D. P.  Stites,  and H. H. Fudenberg.  1970. Wiskott- 
Aldrich syndrome,  a  genetically  determined  cellular  immunologic deficiency: 
clinical  and laboratory responses  to therapy with transfer factor. Proc. Natl. 
Acad. Sci. U.S.A.67:821. 
17.  Spitler,  L. E., A. S. Leven, D. P. Stites, D. P. and H. H. Fudenberg. 1971. Current 
status of transfer factor therapy in the Wiskott-Aldrich Syndrome. Clin. Res. 
29:162. 
18.  Chaparas, S. D., D. E. Thor, H. P. Godfrey, H. Baer, and S. R. Hedrick. 1970. 
Tuberculin-active carbohydrate that induces inhibition of macrophage migra- 
tion but not lymphocyte transformation. Science (Wash. D.C.). 170:637. 
19.  Paterson, P. Y.  1960. Transfer of allergic encephalomyelitis in rats by means of 
lymph node cells. Y. Exp. Med. 111:119. 
20.  Stone, S. H.  1961. Transfer of allergic encephalomyelitis by lymph node cells in 
inbred guinea pigs. Science (Wash. D.C.). 134:619. 
21.  Whitehouse, D. J., M. W. Whitehouse, and C. M. Pearson. 1969. Passive transfer 
of adjuvant-induced arthritis and allergic  encephalomyelitis in rats using thor- 
racic duct lymphocytes. Nature (Lond.) 9.24:1322. 
22.  Kabat,  E. A., A. Wolf, and A. E. Berger.  1948.  Studies on acute disseminated 
encaphalomyelitis produced  experimentally  in rhesus  monkeys. III. Y.  Exp. 
Med. 88:417. 
23.  Paterson, P. Y., and S. M. Harwin.  1963. Suppression of allergic encephalomye- 
litis in rats by means of anti-brain serum. Y. Exp. Med. 117:755. 
24.  Paterson, P. Y., and H. S. Weiss.  1965. Transfer of allergic encephalomyelitis in 
rats by intracerebral injection of lymphoid cells. Proc. Soc. Exp. Biol. Med. 119: 
267. 
25.  Bloom, B. R., and B. Bennett.  1966. Mechanism of a reaction in vitro associated 
with delayed type hypersensitivity. Science (Wash. D.C.). 153:80. 
26.  David, J.  R.  1966. Delayed hypersensitivity in vitro: its mediation by cell free 
substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. 
U.S.A. 56:72. 
27.  Ward, P. A., H. G. Remold, and J. R. David. 1969. Leukotactic factor produced 
by sensitized lymphocytes, Science (Wash. D.C.). 163:1079. 
28.  Kasakura, S., and L. Lowenstein. 1965. A factor stimulating DNA synthesis de- 
rived from the medium of leukocyte cultures. Nature (Lond.). 206:794. 
29.  Spifler, L. E., and H. H. Fudenberg. 1970. Productsof interaction of antigen-sensl- 
tized leukocytes and antigen: further characterization of the mitogenic factor. 
J. Immunol.  104:544. 
30.  Spitler, L. E., and H. S. Lawrence. 1969. Studies of lymphocyte culture: products 
of sensitive lymphocyte-antigen interaction. J. Imrnunol. 103:1072. 174  EAE  WITHOUT CELLULAR  IMMUNITY 
31.  Valentine, F. T., and H. S. Lawrence. 1969. Lymphocyte stimulation: transfer of 
cellular hypersensitivity to antigen in vitro. Science (Wash. D.C.). 165:1014. 
32.  Ruddle, N. H., and B. H. Waksman. 1968. Cytotoxicity mediated by soluble anti- 
gen and lymphocyte in delayed hypersensitivity. III. Analysis of mechanism. 
J. Exp. Meal. 19.8:1237. 
33.  Bennett, B., and B. R. Bloom. 1968. Reactions in vivo and in vitro produced by a 
soluble  substance  associated  with  delayed  type  hypersensitivity.  Proc.  Natl. 
Aead. Sci. U.S.A. 59:756. 
34.  Green, J. A., S. R. Cooperband, and S. Kibrick. 1969. Immune specific induction 
of  interferon  preduction  in  cultures  of  human  blood  lymphocytes.  Science 
(Wash. D.C.). 164:1415. 
35.  Bach, F., and K. tIirschhorn.  1963. Globulin production by human lymphocytes 
in vitro. Exp. Cell Res. 22:592. 
36.  Waksman, B. H., and L. R. Morrison. 1951. Tuberculin type sensitivity to spinal 
cord antigen in rabbits with isoallergic  encephalomyelitis. J. In~munol.  66:421. 
37.  Waksman, B. H. 1956. Further study of skin reactions in rabbits with experimental 
allergic encephalomyelitis.  Reactions to tests with purified white matter frac- 
tions. Use of a  quantitative  technique for evaluating sensitivity production of 
sensitization and disease by intradermal iniection of antigen without adjuvants. 
J. Infect. Dis. 00:258. 
38.  David, J. R., and P. Y. Paterson.  1965. In vitro demonstration of cellular sensi- 
tivity in allergic encephalomyelitis. J. Exp. Med. 19.2:1161. 
39.  Rocklin, R. E., E. J. Lewis, and J. R. David.  1970. In vitro evidence for cellular 
hypersensitivity to glomerular-basement-membrane antigens in human glomer- 
ulonephritis. N. Engl. J. Med. 9,83:497. 
40.  Nerup, J., V. Andersen, and G. Bendixen.  1970. Anti-adrenal cellular hypersensi- 
tivity in Addison's disease.  IV. In vivo and in vitro investigations on the mito- 
chondrial fraction. CIin. Exp. Immunol.  6:733. 
41.  Fixa, B., and H.  G. Thiele.  1969. Delayed hypersensitivity to intrinsic factor in 
patients with pernicious anaemia: a preliminary report. Meal. Exp. 19:231. 
42.  Bendixen,  G.  1967. Specific inhibition  of the in vitro migration of leucocytes in 
ulcerative colitis and Crohn's disease.  Scan& J. Gastroenterol. 9.:214. 
43.  Bartfeld, H., and T. Atoynatan. 1970. In vitro delayed (cellular)  hypersensitivity 
in multiple sclerosis to central nervous system antigens. Int. Arch. AIlergy A ppl. 
Immunol. 39:361. 
44.  Rocldin, R. E., W. A. Sheremata, R. G. Feldman, M. W. Kies, and J. R. David. 
1971. The Guillain-Barr~  syndrome and multiple sclerosis:  i'~ vitro cellular re- 
sponses to nervous-tissue antigens. N. Engl. J. Med. 284:803. 
45.  Bornstein, M. B., and S. H. Appel. 1961. The application of tissue culture to the 
study of experimental  "allergic" encephalomyelitis.  I. Patterns  of demyelina- 
tion. J. NeuropathoL  E~p. Neurol. 20:141. 